Literature DB >> 26397949

Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations.

Ada E D Teo1, Sumedha Garg, Lalarukh Haris Shaikh, Junhua Zhou, Fiona E Karet Frankl, Mark Gurnell, Lisa Happerfield, Alison Marker, Mariann Bienz, Elena A B Azizan, Morris J Brown.   

Abstract

Recent discoveries of somatic mutations permit the recognition of subtypes of aldosterone-producing adenomas with distinct clinical presentations and pathological features. Here we describe three women with hyperaldosteronism, two who presented in pregnancy and one who presented after menopause. Their aldosterone-producing adenomas harbored activating mutations of CTNNB1, encoding β-catenin in the Wnt cell-differentiation pathway, and expressed LHCGR and GNRHR, encoding gonadal receptors, at levels that were more than 100 times as high as the levels in other aldosterone-producing adenomas. The mutations stimulate Wnt activation and cause adrenocortical cells to de-differentiate toward their common adrenal-gonadal precursor cell type. (Funded by grants from the National Institute for Health Research Cambridge Biomedical Research Centre and others.).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397949      PMCID: PMC4612399          DOI: 10.1056/NEJMoa1504869

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  An adverse pregnancy-associated outcome due to overlooked primary aldosteronism.

Authors:  Kazuo Eguchi; Satoshi Hoshide; Shuichi Nagashima; Takashi Maekawa; Hironobu Sasano; Kazuomi Kario
Journal:  Intern Med       Date:  2014-11-01       Impact factor: 1.271

2.  Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors.

Authors:  Elena A B Azizan; Brian Y H Lam; Stephen J Newhouse; Junhua Zhou; Rhoda E Kuc; Jennifer Clarke; Lisa Happerfield; Alison Marker; Gary J Hoffman; Morris J Brown
Journal:  J Clin Endocrinol Metab       Date:  2012-03-22       Impact factor: 5.958

Review 3.  Multiple aberrant hormone receptors in Cushing's syndrome.

Authors:  Nada El Ghorayeb; Isabelle Bourdeau; André Lacroix
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

4.  A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?

Authors:  N M Albiger; P Sartorato; B Mariniello; M Iacobone; I Finco; A Fassina; F Mantero
Journal:  Eur J Endocrinol       Date:  2011-03       Impact factor: 6.664

5.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

6.  Aberrant gonadotropin-releasing hormone receptor (GnRHR) expression and its regulation of CYP11B2 expression and aldosterone production in adrenal aldosterone-producing adenoma (APA).

Authors:  Yasuhiro Nakamura; Namita G Hattangady; Ping Ye; Fumitoshi Satoh; Ryo Morimoto; Takako Ito-Saito; Akira Sugawara; Koji Ohba; Kazuhiro Takahashi; William E Rainey; Hironobu Sasano
Journal:  Mol Cell Endocrinol       Date:  2014-01-25       Impact factor: 4.102

7.  Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study.

Authors:  Sébastien Savard; Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

8.  Lhcgr expression in granulosa cells: roles for PKA-phosphorylated β-catenin, TCF3, and FOXO1.

Authors:  Nathan C Law; Jennifer Weck; Brandon Kyriss; John H Nilson; Mary Hunzicker-Dunn
Journal:  Mol Endocrinol       Date:  2013-06-10

9.  DACH1, a zona glomerulosa selective gene in the human adrenal, activates transforming growth factor-β signaling and suppresses aldosterone secretion.

Authors:  Junhua Zhou; Lalarukh Haris Shaikh; Sudeshna G Neogi; Ian McFarlane; Wanfeng Zhao; Nichola Figg; Cheryl A Brighton; Carmela Maniero; Ada E D Teo; Elena A B Azizan; Morris J Brown
Journal:  Hypertension       Date:  2015-03-16       Impact factor: 10.190

10.  Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension.

Authors:  Elena A B Azizan; Hanne Poulsen; Petronel Tuluc; Junhua Zhou; Michael V Clausen; Andreas Lieb; Carmela Maniero; Sumedha Garg; Elena G Bochukova; Wanfeng Zhao; Lalarukh Haris Shaikh; Cheryl A Brighton; Ada E D Teo; Anthony P Davenport; Tanja Dekkers; Bas Tops; Benno Küsters; Jiri Ceral; Giles S H Yeo; Sudeshna Guha Neogi; Ian McFarlane; Nitzan Rosenfeld; Francesco Marass; James Hadfield; Wojciech Margas; Kanchan Chaggar; Miroslav Solar; Jaap Deinum; Annette C Dolphin; I Sadaf Farooqi; Joerg Striessnig; Poul Nissen; Morris J Brown
Journal:  Nat Genet       Date:  2013-08-04       Impact factor: 38.330

View more
  42 in total

1.  Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series.

Authors:  Francesco Fallo; Isabella Castellano; Celso E Gomez-Sanchez; Yara Rhayem; Catia Pilon; Valentina Vicennati; Donatella Santini; Valeria Maffeis; Ambrogio Fassina; Paolo Mulatero; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

2.  Hypertension in a Pregnant Patient: How I Treat.

Authors:  Phyllis August
Journal:  Clin J Am Soc Nephrol       Date:  2019-07-03       Impact factor: 8.237

Review 3.  PRECISION MEDICINE IN ADRENAL DISORDERS: THE NEXT GENERATION.

Authors:  Hans K Ghayee; Aaron I Vinik; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

Review 4.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

5.  Primary hyperaldosteronism presenting as persistent postpartum hypertension: Illustrative case and systematic review.

Authors:  Caitlin Kilmartin; Touhid Opu; Tiina Podymow; Natalie Dayan
Journal:  Obstet Med       Date:  2018-05-22

Review 6.  Adrenocortical tumorigenesis: Lessons from genetics.

Authors:  Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-05-23       Impact factor: 4.690

7.  Chemogenetic activation of adrenocortical Gq signaling causes hyperaldosteronism and disrupts functional zonation.

Authors:  Matthew J Taylor; Matthew R Ullenbruch; Emily C Frucci; Juilee Rege; Mark S Ansorge; Celso E Gomez-Sanchez; Salma Begum; Edward Laufer; David T Breault; William E Rainey
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

8.  Hypomethylation of CYP11B2 in Aldosterone-Producing Adenoma.

Authors:  Yoko Yoshii; Kenji Oki; Celso E Gomez-Sanchez; Haruya Ohno; Kiyotaka Itcho; Kazuhiro Kobuke; Masayasu Yoneda
Journal:  Hypertension       Date:  2016-10-17       Impact factor: 10.190

Review 9.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

10.  Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17.

Authors:  Yasuhiro Nakamura; Masaaki Kitada; Fumitoshi Satoh; Takashi Maekawa; Ryo Morimoto; Yuto Yamazaki; Kazue Ise; Celso E Gomez-Sanchez; Sadayoshi Ito; Yoichi Arai; Mari Dezawa; Hironobu Sasano
Journal:  Mol Cell Endocrinol       Date:  2015-11-17       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.